mgmt promoter methylation status testing Search Results


mgmt gene promoter methylation status  (LabCorp)
90
LabCorp mgmt gene promoter methylation status
A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the <t>MGMT</t> (O <t>6</t> <t>-methylguanine-DNA</t> methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.
Mgmt Gene Promoter Methylation Status, supplied by LabCorp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mgmt gene promoter methylation status/product/LabCorp
Average 90 stars, based on 1 article reviews
mgmt gene promoter methylation status - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mgmt promoter methylation testing  (MDxHealth)
90
MDxHealth mgmt promoter methylation testing
A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the <t>MGMT</t> (O <t>6</t> <t>-methylguanine-DNA</t> methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.
Mgmt Promoter Methylation Testing, supplied by MDxHealth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mgmt promoter methylation testing/product/MDxHealth
Average 90 stars, based on 1 article reviews
mgmt promoter methylation testing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mgmt promoter methylation status testing  (Covance)
90
Covance mgmt promoter methylation status testing
A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the <t>MGMT</t> (O <t>6</t> <t>-methylguanine-DNA</t> methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.
Mgmt Promoter Methylation Status Testing, supplied by Covance, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mgmt promoter methylation status testing/product/Covance
Average 90 stars, based on 1 article reviews
mgmt promoter methylation status testing - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
promoter methylation status of the mgmt gene  (Illumina Inc)
90
Illumina Inc promoter methylation status of the mgmt gene
A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the <t>MGMT</t> (O <t>6</t> <t>-methylguanine-DNA</t> methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.
Promoter Methylation Status Of The Mgmt Gene, supplied by Illumina Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/promoter methylation status of the mgmt gene/product/Illumina Inc
Average 90 stars, based on 1 article reviews
promoter methylation status of the mgmt gene - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
methyl-guanosine methyl transferase (mgmt) promoter methylation status  (Pyrosequencing Inc)
90
Pyrosequencing Inc methyl-guanosine methyl transferase (mgmt) promoter methylation status
Pathological and molecular characteristics according to IDH1 G105G SNP status.
Methyl Guanosine Methyl Transferase (Mgmt) Promoter Methylation Status, supplied by Pyrosequencing Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/methyl-guanosine methyl transferase (mgmt) promoter methylation status/product/Pyrosequencing Inc
Average 90 stars, based on 1 article reviews
methyl-guanosine methyl transferase (mgmt) promoter methylation status - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
dna methylation status of mgmt promoter  (Janssen)
90
Janssen dna methylation status of mgmt promoter
Pathological and molecular characteristics according to IDH1 G105G SNP status.
Dna Methylation Status Of Mgmt Promoter, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna methylation status of mgmt promoter/product/Janssen
Average 90 stars, based on 1 article reviews
dna methylation status of mgmt promoter - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the MGMT (O 6 -methylguanine-DNA methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.

Journal: JAMA Oncology

Article Title: Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

doi: 10.1001/jamaoncol.2022.5370

Figure Lengend Snippet: A, Kaplan-Meier plot comparing overall survival for patients with newly diagnosed glioblastoma treated with autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) and 1366 contemporaneous matched external control participants (ECPs) treated with standard of care, derived from 5 other contemporaneous matched randomized clinical trials. B, Cox hazard ratios of overall survival in prespecified subgroups of participants receiving DCVax-L or treated with standard of care in external trials. In the age subgroup, there were 50 participants in the DCVax-L group and 45 in the ECP group aged 65 years or greater and 182 and 184, respectively in the younger than 65 years group; in the residual disease subgroup, there were 86 patients in the DCVax-L group and 163 in the ECP group with significant residual disease and 146 and 210, respectively, with minimal residual disease; in the MGMT (O 6 -methylguanine-DNA methyltransferase) subgroup, there were 90 patients in the DCVax-L group and 199 in the ECP group with methylated MGMT and 131 and 349, respectively, with unmethylated MGMT. Subgroup analyses of survival, using the same parameters as the comparator publications, are presented with 95% confidence intervals to facilitate comparisons with the ECP.

Article Snippet: The MGMT (O 6 -methylguanine-DNA methyltransferase) gene promoter methylation status, IDH (isocitrate dehydrogenase) R132 mutation status, and postsurgery minimal (<2 cm 2 ) vs significant (≥2 cm 2 ) residual tumor were determined centrally (LabCorp; Mayo; ICON).

Techniques: Control, Derivative Assay, Clinical Proteomics, Methylation

Pathological and molecular characteristics according to IDH1 G105G SNP status.

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: Pathological and molecular characteristics according to IDH1 G105G SNP status.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation

PFS analysis of clinical/pathological/molecular features by Cox regression.

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: PFS analysis of clinical/pathological/molecular features by Cox regression.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation

DSS analysis of clinical/pathological/molecular features by Cox regression.

Journal: Genes

Article Title: Prognostic Analysis of the IDH1 G105G (rs11554137) SNP in IDH-Wildtype Glioblastoma

doi: 10.3390/genes13081439

Figure Lengend Snippet: DSS analysis of clinical/pathological/molecular features by Cox regression.

Article Snippet: Methyl-guanosine methyl transferase (MGMT) promoter methylation status has been analyzed by pyrosequencing, using a ≥9% average methylation level of CpG islands to define the methylated cases, according to Dunn J et al. [ ].

Techniques: Methylation